Opdivo Survival Data Support PD-1 Upfront In Melanoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Results from CheckMate-066 presented at the annual melanoma meeting show Bristol’s Opdivo improves survival over chemotherapy – which performed better than usual due to follow-up treatment with the company’s CTLA-4 inhibitor Yervoy.